23 results
Thumbnail

D3.278 - Cold urticaria: a case report

Thumbnail

D3.279 - Biomarkers in anaphylaxis

Thumbnail

D3.282 - Anaphylaxis to Gadoteric Acid: A Case Report

Thumbnail

D3.283 - Taming the Unpredictable: Omalizumab’s Role in Idiopathic anaphylaxis and chronic spontaneous urticaria

Thumbnail

D3.284 - Update of the Brazilian Anaphylaxis Registry

Thumbnail

D3.285 - Improving Emergency Department Management of Adult Anaphylaxis: A Quality Improvement Initiative

Thumbnail

D3.286 - Rapid Symptom Resolution in Oral Allergy Syndrome Following Anaphylm Administration: A Phase 2 Study Update

Thumbnail

D3.287 - Adverse reactions and complications of Allergic Skin Test (SPT) in North Indian population

Thumbnail

D3.288 - Asthma and Anaphylaxis Induced by Milk with NSAID as a Cofactor in Adult Patient Sensitized to Dairy Proteins Due to Environmental Exposure in a Dairy Farm

Thumbnail

D3.289 - Pharmacokinetics of adrenaline administered via the ZiBiPen: First human trial findings

Thumbnail

D2.332 - Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group

Thumbnail

D2.325 - Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Thumbnail

D2.326 - Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study

Thumbnail

D2.327 - Outcome of hematopoietic stem cells transplantation for inborn error of immunity in Vietnam

Thumbnail

D2.328 - Comparison of the frequency of viral infections in immunocompromised patients receiving immunoglobulin by different routes

Thumbnail

D2.329 - Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials

Thumbnail

D2.330 - Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile

Thumbnail

D2.331 - Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study

Thumbnail

D2.334 - Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: A 12-Month Retrospective Study at a Single Center in Colombia

Thumbnail

D2.336 - Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)